GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $116.24 and last traded at $112.57, with a volume of 448738 shares. The stock had previously closed at $111.01.
Analyst Upgrades and Downgrades
WGS has been the topic of a number of recent analyst reports. TD Cowen raised their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a report on Tuesday, January 7th. Wells Fargo & Company decreased their target price on GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a report on Thursday. TD Securities dropped their target price on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research report on Thursday. Finally, The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $78.14.
View Our Latest Stock Report on WGS
GeneDx Stock Down 2.9 %
The company has a market cap of $1.82 billion, a P/E ratio of -33.10 and a beta of 1.93. The company's 50-day moving average is $95.53 and its two-hundred day moving average is $82.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.
GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.17. The business had revenue of $87.12 million for the quarter, compared to analysts' expectations of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. As a group, equities analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Katherine Stueland sold 46,594 shares of GeneDx stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $89.62, for a total transaction of $4,175,754.28. Following the transaction, the chief executive officer now owns 1,720 shares in the company, valued at approximately $154,146.40. The trade was a 96.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Feeley sold 922 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $94.72, for a total value of $87,331.84. Following the completion of the sale, the chief financial officer now owns 5,446 shares of the company's stock, valued at $515,845.12. The trade was a 14.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 136,848 shares of company stock valued at $12,755,813 in the last ninety days. Corporate insiders own 27.30% of the company's stock.
Institutional Trading of GeneDx
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. MCF Advisors LLC raised its position in shares of GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after buying an additional 182 shares during the last quarter. Sterling Capital Management LLC increased its holdings in GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after acquiring an additional 316 shares during the last quarter. Global Retirement Partners LLC bought a new stake in GeneDx in the 4th quarter valued at $28,000. Lazard Asset Management LLC purchased a new stake in GeneDx in the 4th quarter worth $35,000. Finally, GAMMA Investing LLC boosted its holdings in shares of GeneDx by 151.7% during the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after purchasing an additional 264 shares during the last quarter. Institutional investors own 61.72% of the company's stock.
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
